Seleziona una pagina

Caring for Calcium-Related Rare Diseases

Caring for Calcium-Related Rare Diseases

A Start Up founded in December 2016 and committed to the discovery and development of orphan drugs for patients affected by calcium-related genetic diseases. ChemICare’s mission is the improvement of the quality of life of patients affected by Tubular Aggregate Myopathy, York Platelet SyndromeStormorken Syndrome and Acute Pancreatitis by the development of a therapy that restores the abnormal intracellular calcium level, a common feature of these three rare diseases.





ChemICare’s efforts have resulted in the generation of a number of unique and potent inhibitors of the Store Operated Calcium Entry. These compounds have demonstrated to restore the intracellular calcium levels to physiological levels, to be effective in biopsies of patients affected by Tubular Aggregate Myopathy and are currently being evaluated in transgenic mouse models. We believe these molecules could represent a therapeutic treatment for people affected by rare pathologies related to gain-of-function mutations of STIM1 and Orai1.


ChemICare targets a cluster of rare diseases currently without therapy: Tubular Aggregate Myopathy (TAM), characterized by painful contractures and progressive skeletal muscle degeneration, York platelet Syndrome (YPS), where the main hallmark is the abnormal bleeding, and Stormorken Syndrome (STRMK), a combination of the previous two pathologies. These three diseases are caused by gain-of-function mutations in Orai1 and STIM1, which cause an abnormal increase in intracellular calcium levels.  MORE



ChemICare’s research is focused on a specific cellular event, the Store Operated Calcium Entry (SOCE), also known as capacitative calcium entry. This is a specialized form of calcium influx that involves a close communication between the plasma membrane and the endoplasmic reticulum. In particular, in SOCE, the depletion of calcium from the endoplasmic reticulum triggers calcium influx across the plasma membrane. MORE                                                                                                                                                                                                                                                                                                                     .

Different rare diseases

Millions people affected worldwide


Affect children


Has a drug treatment




4 + 8 =

ChemICare srl  – P:IVA 02505930038

Via Amico Canobio 4/6, Novara

Informativa cookies

This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 868652